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Abstract
Background. Conversion to sirolimus from calcineurin
inhibitor- (CNI), azathioprine- (AZA) and mycopheno-
late-based regimens reduces the risk of development of
squamous cell carcinoma of the skin (SCC) in kidney
transplant recipients (KTRs). Sirolimus conversion may
also be protective by permitting beneﬁcial changes in
immune phenotype. It is not known how sirolimus will
affect immune phenotype in KTRs with SCC.
Methods. Thirty-two KTRs with SCC were enrolled
into this single-blinded randomized study and 13 KTRs
randomized to sirolimus (4–10 ng/mL) and prednisolone
5 mg/day.
Results. Six-month post conversion to sirolimus FOXP3+
CD127lowCD25highCD69−, the number of T cells (putative
Treg) increased signiﬁcantly (P = 0.008). Natural killer
(NK) and CD56bright NK cells also increased signiﬁcantly
(P = 0.039 and 0.02). T-cell number only signiﬁcantly in-
creased in those KTRs where CNI was ceased as part of the
conversion to mammalian target of rapamycin inhibitors
(mTORi’s) (P = 0.031) implying CNI cessation rather than
mTORi initiation induced an increase in T-cell number. In-
creases in the NK cell number was only signiﬁcant in those
KTRs where AZA was ceased (P = 0.040), implying AZA
cessation rather than mTORi initiation caused the NK cell
number to increase. At 6 months, sirolimus conversion
reduces new SCC/year, rate ratio 0.49 (95%CI: 0.15–1.63),
P = 0.276. On therapy analysis and intention-to-treat analy-
sis over 24 months, the rate ratios were 0.84 and 0.87,
respectively, and did not reach signiﬁcance.
Conclusions. Conversion to mTORi from CNI may reveal
a pre-existing high Treg phenotype by unmasking CNI inhi-
bition of FOXP3 expression. Cessation of AZA leads to in-
creased NK cell number. High FOXP3+ T-cell number on
conversion to mTORi may predict those KTRs who con-
tinue to accrue SCC.
Keywords: immune phenotype; mTOR inhibitors; skin cancer; Treg
Introduction
Mammalian target of rapamycin inhibitors (mTORi’s)
have been shown to slow or reduce the development of de
novo cancer in kidney transplant recipients (KTRs) [1–3].
The effect of sirolimus on cell proliferation and neovascu-
larization are potential mechanisms by which sirolimus
prevents the development of malignancy [4–7].
Another possible mechanism is that sirolimus-based re-
gimens are quantitatively less immunosuppressive, and it
is known that reductions in immunosuppression reduce
the risk of cancer [8] and metastasis [9]. One way of de-
termining this is to deﬁne whether rejection rates are
higher after sirolimus conversion or in comparison to cal-
cineurin inhibitor (CNI)-based regimens. There were
small, but statistically non-signiﬁcant, increases in rejec-
tion after conversion to sirolimus in the CONVERT study
and no rejection at all in long-term transplant with pre-
vious non-melanoma skin cancers (NMSCs) converted to
sirolimus [3, 10, 11]. The increased rates of rejection in
the SYMPHONY study may reﬂect sub-therapeutic
dosing of sirolimus [12, 13]. Using acute rejection as a
readout, there is no objective evidence that sirolimus regi-
mens are quantitatively less immunosuppressive.
Another possible mechanism by which mTORi may
have anti-cancer effects is via differential effects on
immune cells in comparison to conventional immunosup-
pression. In KTR with a low CD4 count, high Treg
numbers and low natural killer (NK) cell numbers, there
is increased risk of cancer [14–16]. Importantly, these
immune phenotypes were generated in KTR cohorts not
treated with mTORi. mTORi preferentially allow the ex-
pansion and generation of Treg and CNI prevent the
expression of FOXP3, the Treg master regulatory gene
[17–19]. It is plausible therefore that induction of
FOXP3+ T cells by mTORi initiation or CNI cessation
may paradoxically oppose mTORi anti-cancer
mechanisms.
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Up to 40% of KTR on mTORi still accrue SCC and/or
solid-organ cancer and immune phenotype changes after
conversion to mTORi may therefore predict KTR who
still develop cancer on mTORi.
The RESCUE trial has shown that randomized conver-
sion to mTORi and cessation of CNI, azathioprine (AZA)
and mycophenolate in KTR with SCC skin was signiﬁ-
cantly associated with a reduced accrual of new SCC
tumours in KTR with previous SCC. We therefore
hypothesized that conversion would be associated with
signiﬁcant changes in immune phenotype of peripherally
circulating lymphocytes.
Materials and methods
Patient characteristics are presented in Table 1. All patients provided in-
formed consent, and the study was approved by a multicentre ethics
committee and performed according to STROBE guidelines [20]. The
study group consisted of 32 of the 155 white KTR with a functioning
transplant and at least one histologically diagnosed SCC recruited to the
RESCUE study. Patients from centres in Birmingham, Cardiff, London
and Oxfordshire were invited to consent to immune cell monitoring.
After a baseline dermatological assessment, patients were randomized
to stay on current therapy or switch to 5 mg of prednisolone and siroli-
mus (trough levels 5–10 ng/mL). Every 3 months, until 2 years of
follow-up, patients were assessed by a dermatologist and any suspicious
lesions biopsied and/or resected. The dermatologist was blinded to the
randomization status of the patient. At baseline, 3, 6 and 24 months,
these patients were also immune phenotyped with the laboratory tech-
nician blinded to the randomization status.
Immune phenotyping was performed on peripheral blood within 2-h
venesection as described previously [16]. In brief, peripheral blood was
collected from KTR during trough levels of CNI and mTORi. Peripheral
blood mononuclear cells were separated from whole blood by standard
centrifugation and Ficoll techniques. Lymphocytes were stained with
multiple monoclonal antibodies conjugated to ﬂuorochromes to elucidate
FOXP3+CD127lowCD25highCD69− T cells and CD56bright/dimCD16+
CD3−CD19− NK cells via ﬂow cytometry. Absolute cell counts were
calculated from lymphocyte counts from concurrent routine haematology
laboratory results and the proportion of each cell type in the lymph gate
from the ﬂow cytometer data.
Statistical analysis was performed using Graph Pad Prism, version
5.0d. Changes in immune phenotype were assessed by Wilcoxon signed-
rank test using patients as their internal controls. Analysis of differences
between KTR converted and not converted use the Mann–Whitney two-
tailed test for continuous variables, and Fischer’s exact two-tailed test for
proportions. The number of SCC per year of follow-up was calculated
from the Poisson analysis of those KTR on sirolimus versus those not on
sirolimus using STATA 12.
Results
Thirteen KTRs were randomized to sirolimus and 19
KTRs were not converted. At 2 months, one KTR was no
longer on therapy. At 7 months, four more KTRs were no
longer on sirolimus due to side effects. By 24 months,
immune phenotype data were collected on three KTRs on
sirolmus and 18 KTRs not on sirolimus.
At 6 months, the number of SCC/year follow-up were
as follows: 1.25 SCC/per year in non-converted group
and 0.62 SCC/year in the sirolimus group; for those, the
converted rate ratio (RR) was 0.49 (95% CI: 0.15–1.63),
P = 0.276. On an intention-to-treat analysis over 24
months, 0.73 SCC/year in non-converted and 0.61 SCC/
year in the sirolimus group; RR 0.84 (95% CI: 0.43–
1.62), P = 0.565. On therapy analysis was similar: RR
0.87 (95% CI: 0.40–1.92), P = 0.726. Due to the small
number of subjects, adjustment for sex, age and previous
number of SCC was not performed. These parameters
were not different between the groups (Table 1).
The changes in immune phenotype over time are
shown in Figures 1 and 2 and represent those KTR on
therapy at any given time point. There were signiﬁcant in-
creases in FOXP3+ T cell and NK cell numbers in those
converted to sirolimus that reached statistical signiﬁcance
Table 1. Demographic data of those KTR randomized to sirolimus












10 (77) 14 (74) 1.000
CNI-based regimen
(n [%])
8 (62) 15 (79) 0.427
Male (n [%]) 9 (69) 18 (94) 0.132
Age (years) 64 (46–72) 59 (47–81) 0.984
Duration of immune
suppression (years)




2 (1–26) 3 (1–9) 1.000
Differences in continuous variables assessed by Mann–Whitney two-
tailed test and for categorical variables by Fisher’s exact two-tailed test.
Fig. 1. Box plot (median, range) of changes in FOXP3+ T cells from the
study entry (baseline) to various time points after randomization. Clear
bars represent those kidney transplant patients not on sirolimus at that
time point. Stippled box plots represent KTR converted to sirolimus and
who stayed on therapy (n = 13 randomized to conversion, n = 11 at 3 and
6 months and n = 3 at 24 months). Assessment of changes from baseline
to 6 months by Wilcoxon signed-rank test. Comparison between groups
at 6 months Mann–Whitney two-tailed test.










at 6 months, P = 0.008 and 0.039, respectively. Figures 3
and 4 represent the changes in immune phenotype in
those who did or did not cease CNI as part of conversion
to sirolimus (Figure 3) and those who did or did not cease
AZA as part of the conversion to mTORi (Figure 4).
Only those KTR who ceased CNI had signiﬁcant in-
creased in FOXP3+ T cells (P = 0.031) and only those
who ceased AZA high signiﬁcant increases in NK cells
(P = 0.040)
Discussion
We have shown that there are signiﬁcant and sustained
changes in immune phenotype which occur when KTR
are converted to mTORi from other immunosuppressive
drug regimens (Figures 1 and 2). These changes are slow
in development, taking 6 months to develop. Although an
increasing disparity in FOXP3+ T cell and NK cell
numbers was observed at 24 months, the data were not
analysed statistically due to the small numbers of KTR
remaining on mTORi. This prolonged time-to-effect may
be due to the prolonged effects of AZA on bone marrow
suppression after decades of usage, in particular given
that the median duration of immunosuppression in this
group approached 20 years.
Sub-group analysis revealed that cessation of CNI and
AZA are most likely the cause of these changes rather
than initiation of mTORi (Figures 3 and 4). mTORi
initiation/CNI-AZA cessation increased both FOXP3+
T cells and NK cells. The increases in FOXP3+ T would
be expected to increase the risk of subsequent SCC devel-
opment and the increase in NK cell number would be ex-
pected to be protective for SCC development. Therefore,
Fig. 4. Box plot (median and range) of changes in NK cell numbers
from randomization to 6 months in those KTR converted to sirolimus
(n = 13). ‘No AZA pre’ represents those KTR not on AZA based
regimens prior to conversion to sirolimus. ‘AZA pre’ represents those
KTR on AZA prior to conversion to sirolimus. Only KTR where AZA
was ceased as part of conversion to sirolimus had a signiﬁcant increase
in NK cell numbers.
Fig. 2. Box plot (median, range) of changes in NK cell number from
the study entry (baseline) to various time points after randomization.
Clear bars represent those kidney transplant patients not on sirolimus at
that time point. Stippled box plots represent KTR converted to sirolimus
and who stayed on therapy (n = 13 randomized to conversion, n = 11 at 3
and 6 months and n = 3 at 24 months). Assessment of changes from
baseline to 6 months by Wilcoxon signed-rank test. Comparison between
groups at 6 months Mann–Whitney two-tailed test.
Fig. 3. Box plot (median and range) of changes in FOXP3+ T cells from
randomization to 6 months in those KTR converted to sirolimus (n = 13).
‘CNI pre’ represents those KTR on calcineurin (CNI)-based regimens
prior to conversion to sirolimus. ‘No CNI’ pre represents those KTR not
on calcineurin prior to conversion to sirolimus. Only KTR where CNI
was ceased as part of conversion to sirolimus had a signiﬁcant increase
in FOXP3+ T cell numbers.










there are potential opposing changes in immune pheno-
type in this cohort, although statistically the changes in
FOXP3+ T cells were more pronounced, and this ﬁnding
may inform subsequent SCC development.
In the RESCUE study total population (n = 155), the
RR for SCC for conversion was 0.43 and reached statisti-
cal signiﬁcance. The sub-study reported here was never
intended to be powered to detect differences in tumour
accrual between drug regimens but did show RR of 0.49–
0.89 depending on the duration of follow-up, though not
reaching signiﬁcance.
A plausible explanation therefore is that if FOXP3+ T-
cell numbers increase with cessation with CNI and/or
conversion to sirolimus, this may deﬁne a population of
KTR who continue to accrue SCC in spite of the anti-pro-
liferative or other proposed anti-cancer effects of siroli-
mus. Indeed, when tumour accrual for the entire group
(n = 32) is assessed, irrespective of drug regimen, the
median number of FOXP3+ T cells were higher in KTRs
who developed SCC but did not reach statistical signiﬁ-
cance (data not shown).
In summary, it would seem that conversion to sirolimus
and cessation of CNI’s and AZA is associated with sig-
niﬁcant changes in immune phenotype that are slow in
time course to develop but are prolonged. Particular
changes in immune phenotype may deﬁne those at risk of
new SCC development and may deﬁne those who may
still accrue SCC on sirolimus.
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